Influenza vaccine-live

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 294-311

  Luke, Catherine J ^a   Lakdawala, Seema S ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902068728     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00027-6     Document Type: Chapter

References (254)

1. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 1967, 213:612-614.
2. Jin H., Lu B., Zhou H., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306:18-24.
3. Chen Z., Aspelund A., Kemble G., et al. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 2006, 345:416-423.
4. Block S.L., Yi T., Sheldon E., et al. A randomized double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29:9391-9397.
5. Block S.L., Falloon J., Hirschfield J.A. The immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Ped Inf Dis J 2012, March 29. E pub ahead of print. DOI:10.1097/INF.0b013e31825687b0.
6. Belshe R.B., Edwards K.M., Vesikari T., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
7. Monto A.S., Ohmit S.E., Petrie J.G., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
8. Ohmit S.E., Victor J.C., Rotthoff J.R., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
9. Block S.L., Toback S.L., Yi T., et al. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther 2009, 31:2140-2147.
10. Ambrose C.S., Luke C., Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008, 2:193-202.
11. Rhorer J., Ambrose C.S., Dickinson S., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
12. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
13. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
14. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
15. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-9):1-25.
16. Centers for Disease Control and Prevention Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010, 59:1057-1062.
17. Monto A.S., Kioumehr F. The Tecumseh Study of Respiratory Illness, IX: occurence of influenza in the community, 1966-1971. Am J Epidemiol 1975, 102:553-563.
18. Philip R.N., Bell J.A., Davis D.J., et al. Epidemiologic studies on influenza in familial and general population groups, 1951-1956, II: characteristics of occurrence. Am J Hyg 1961, 73:123-137.
19. Fox J.P., Hall C.E., Cooney M.K., et al. Influenzavirus infections in Seattle families, 1975-1979, I: study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982, 116:212-227.
20. Foy H.M., Cooney M.K., Allan I. Longitudinal studies of types A and B influenza among Seattle schoolchildren and families, 1968-74. J Infect Dis 1976, 134:362-369.
21. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982, 4:25-44.
22. Bridges C.B., Fukuda K., Uyeki T.M., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002, 51(RR-3):1-31.
23. Murphy B.R., Clements M.L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989, 146:107-116.
24. Thomas P.G., Keating R., Hulse-Post D.J., et al. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12:48-54.
25. Hancock K., Veguilla V., Lu X., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
26. Itoh Y., Shinya K., Kiso M., et al. In and in characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
27. Palese P., Shaw M.L. Orthomyxoviridae: the viruses and their replication. Fields Virology 2007, 1647-1689. Lippincott, Williams & Wilkins, Philadelphia, PA. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin (Eds.).
28. Wright P.F., Neumann G., Kawaoka Y. Orthomyxoviruses. Fields Virology 2007, 1691-1740. Lippincott, Williams & Wilkins, Philadelphia, PA. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin (Eds.).
29. Burnet F.M. Principles of Animal Virology 1955, Academic Press, New York.
30. Webster R.G., Bean W.J., Gorman O.T., et al. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
31. Webster R.G., Laver W.G., Air G.M., et al. Molecular mechanisms of variation in influenza viruses. Nature 1982, 296:115-121.
32. Both G.W., Sleigh M.J. Complete nucleotide sequence of the haemagglutinin gene from a human influenza virus of the Hong Kong subtype. Nucleic Acids Res 1980, 8:2561-2575.
33. Krystal M., Buonagurio D., Young J.F., et al. Sequential mutations in the NS genes of influenza virus field strains. J Virol 1983, 45:547-554.
34. Palese P., Young J.F. Molecular epidemiology of influenza virus. Genetics of Influenza Viruses 1983, 321-336. Springer-Verlag, Vienna. P. Palese, D.W. Kingsbury (Eds.).
35. Webster R.G., Laver W.G., Air G.M. Antigenic variation among type A influenza viruses. Genetics of Influenza Viruses 1983, 309-322. Springer-Verlag, Vienna. P. Palese, D.W. Kingsbury (Eds.).
36. Burnet F.M., Lind P.E. Recombination of characters between two influenza virus strains. Aust J Sci 1949, 12:109-110.
37. Hirst G.K., Gotlieb T. The experimental production of combination forms of virus, II: a study of serial passage in the allantoic sac of agents that combine the antigens of two disctinct influenza A strains. J Exp Med 1953, 98:53-70.
38. Douglas G.R. Influenza in man. The Influenza Viruses and Influenza 1975, 395-447. Academic Press, New York. E.D. Kilbourne (Ed.).
39. Klenk H.D., Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988, 34:247-281.
40. Stuart-Harris C.H. Influenza and Other Virus Infections of the Respiratory Tract 1965, Williams & Wilkins, Baltimore.
41. Stuart-Harris C.H. Influenza: the human disease. Influenza, the Viruses and the Disease 1976, Publishing Sciences Group, Littleton, MA. C.H. Stuart-Harris, G.C. Schild (Eds.).
42. Tateno I., Suzuki S., Nakamura S., et al. Rapid diagnosis of influenza by means of fluorescent antibody technic, I: some basic informations. Jpn J Exp Med 1965, 383-400.
43. Mulder J., Hers J.F. Influenza 1972, Wolters-Noordhoff, Groningen, Netherlands.
44. Smith H., Sweet C. Pathogenesis of influenza virus infection in ferrets: a model for human influenza. The Molecular Virology and Epidemiology of Influenza 1984, 175-194. Academic Press, New York. C.H. Stuart-Harris, C.W. Potter (Eds.).
45. Naficy K. Human influenza infection with proved viremia: report of a case. N Engl J Med 1963, 269:964-966.
46. Stanley E.D., Jackson G.G. Viremia in Asian influenza. Trans Assoc Am Physicians 1966, 79:376-387.
47. Khakpour M., Saidi A., Naficy K. Proved viraemia in Asian influenza (Hong Kong variant) during incubation period. Br Med J 1969, 4:208-209.
48. Minuse E., Willis P.W., Davenport F.M., et al. An attempt to demonstrate viremia in cases of Asian influenza. J Lab Clin Med 1962, 59:1016-1019.
49. Morris J.A., Kasel J.A., Saglam M., et al. Immunity to influenza as related to antibody levels. N Engl J Med 1966, 274:527-535.
50. Shaw M.W., Arden N.H., Maassab H.F. New aspects of influenza viruses. Clin Microbiol Rev 1992, 5:74-92.
51. Chanock R.M., Murphy B.R., Lai C.-J., et al. Prospects for stabilization of attenuation. The Molecular Virology and Epidemiology of Influenza 1984, 115-120. Academic Press, New York. C.H. Stuart-Harris, C.W. Potter (Eds.).
52. Francis T.J., Maassab H.F. Influenza viruses. Viral and Rickettsial Infections of Man 1965, 689-740. JB Lippincott, Philadelphia, PA. F.L.J. Horsfall, I. Tarur (Eds.).
53. Mackenzie J.S. Virulence of temperature-sensitive mutants of influenza virus. Br Med J 1969, 3:757-758.
54. Maassab H.F. Development of variants of influenza virus. The Biology of Large RNA Viruses 1970, 542-546. Academic Press, New York. R.D. Barry, B.W.J. Mahy (Eds.).
55. Herlocher M.L., Maassab H.F., Webster R.G. Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus. Proc Natl Acad Sci U S A 1993, 90:6032-6036.
56. Davenport F.M., Hennessy A.V., Maassab H.F., et al. Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis 1977, 136:17-25.
57. Maassab H.F., Monto A.S., DeBorde D.C., et al. Development of cold recombinants of influenza virus as live virus vaccines. Genetic Variation among Influenza Viruses 1981, 617-637. Academic Press, New York. D.P. Nayak, C.F. Fox (Eds.).
58. Monto A.S., Miller F.D., Maassab H.F. Evaluation of an attenuated, cold-recombinant influenza B virus vaccine. J Infect Dis 1982, 145:57-64.
59. Ghendon Y.Z., Klimov A.I., Alexandrova G.I., et al. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains. J Gen Virol 1981, 53:215-224.
60. Ghendon Y.Z., Polezhaev F.I., Lisovskaya K.V., et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 1984, 44:730-733.
61. Wright P.F., Okabe N., McKee K.T.J., et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982, 146:71-79.
62. Zaky D.A., Douglas R.G., Betts R.F., et al. Safety and efficacy of "Alice" influenza virus vaccine in normal healthy adults. J Infect Dis 1976, 133:669-675.
63. Beare A.S., Hall T.S. Recombinant influenza-A viruses as live vaccines for man. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines. Lancet 1971, 2:1271-1273.
64. Beare A.S., Schild G.C., Craig J.W. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet 1975, 2:729-732.
65. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 1969, 41:643-645.
66. Murphy B.R., Chanock R.M. Genetic approaches to the prevention of influenza A virus infection. Genetic Variation among Influenza Viruses 1981, 601-616. Academic Press, New York. D.P. Nayak, C.F. Fox (Eds.).
67. Murphy B.R., Tolpin M.D., Massicot J.G., et al. Escape of a highly defective influenza A virus mutant from its temperature sensitive phenotype by extragenic suppression and other types of mutation. Ann N Y Acad Sci 1980, 354:172-182.
68. Tolpin M.D., Clements M.L., Levine M.M., et al. Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses. Infect Immun 1982, 36:645-650.
69. McCahon D., Beare A.S., Stealey V. The production of live attenuated influenza A strains by recombination with A/Okuda/57 (H2N2). Postgrad Med J 1976, 52:389-394.
70. Beare A.S. Research into the immunization of humans against influenza by means of living viruses. Basic and Applied Influenza Research 1982, 110-115. CRC Press, Boca Raton, FL. A.S. Beare (Ed.).
71. Murphy B.R., Sly D.L., Tierney E.L., et al. Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science 1982, 218:1330-1332.
72. Steinhoff M.C., Halsey N.A., Fries L.F., et al. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. J Infect Dis 1991, 163:1023-1028.
73. Steinhoff M.C., Halsey N.A., Wilson M.H., et al. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. J Infect Dis 1990, 162:394-401.
74. Kim H.W., Arrobio J.O., Brandt C.D., et al. Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/86-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen. Pediatr Res 1976, 10:238-242.
75. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 1967, 213:612-614.
76. Alexandrova G.I., Polezhaev F.I., Budilovsky G.N., et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun 1984, 44:734-739.
77. Beare A.S., Bynoe M.L., Tyrrell D.A. Investigation into the attenuation of influenza viruses by serial passage. Br Med J 1968, 4:482-484.
78. Burnet F.M., Bull D.R. Changes in influenza virus associated with adaptation to passage in chick embryos. Aust J Exp Biol Med Sci 1943, 21:55-69.
79. Wacheck V., Egorov A., Groiss F., et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010, 201:354-362.
80. Hatta Y., Hatta M., Bilsel P., et al. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus. Vaccine 2011, 29:2308-2312.
81. Mueller S., Coleman J.R., Papamichal D., et al. Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol 2010, 28:723-726.
82. Simpson R.W., Hirst G.K. Temperature-sensitive mutants of influenza A virus: isolation of mutants and preliminary observations on genetic recombination and complementation. Virology 1968, 35:41-49.
83. Jin H., Lu B., Zhou H., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306:18-24.
84. Jin H., Zhou H., Lu B., et al. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J Virol 2004, 78:995-998.
85. Chen Z., Aspelund A., Kemble G., et al. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 2006, 345:416-423.
86. Donabedian A.M., DeBorde D.C., Cook S., et al. A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology 1988, 163:444-451.
87. Hoffmann E., Mahmood K., Chen Z., et al. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 2005, 79:11014-11021.
88. Alexandrova G.I., Garmashova L.M., Gollubev D.B., et al. Experience in selection of safe thermosensitive recombinants of influenza virus [in Russian]. Vopr Virusol 1979, 4:342-346.
89. Kendal A.P., Maassab H.F., Alexandrova G.I., et al. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A and U.S.S.R. Antiviral Res 1981, 1:339-365.
90. Cox N.J., Kendal A.P., Shilov A.A., et al. Comparative studies of A/Leningrad/134/57 wild-type and 47-times passaged cold-adapted mutant influenza viruses: oligonucleotide mapping and RNA-RNA hybridization studies. J Gen Virol 1985, 66:1697-1704.
91. Isakova-Sivak I., Chen L.-M., Matsuoka Y., et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 2011, 412:297-305.
92. Luytjes W., Krystal M., Enami M., et al. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989, 59:1107-1113.
93. Fodor E., Devenish L., Engelhardt O.G., et al. Rescue of influenza A virus from recombinant DNA. J Virol 1999, 73:9679-9682.
94. Neumann G., Watanabe T., Ito H., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999, 96:9345-9350.
95. Hoffmann E., Neumann G., Kawaoka Y., et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000, 97:6108-6113.
96. Chen Z., Wang W., Zhou H., et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84:44-51.
97. Suguitan A.L., McAuliffe J., Mills K.L., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3:e360.
98. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28S:D45-D53.
99. Reed C., Meltzer M.I., Finelli L., et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
100. Block S.L., Yi T., Sheldon E., et al. A randomized double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29:9391-9397.
101. Block S.L., Falloon J., Hirschfield J.A. et al 2012, The immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children, Ped Inf Dis J, March 29. E pub ahead of print. DOI:10.1097/INF.0b013e31825687b0.
102. Ohmit S.E., Victor J.C., Teich E.R., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198:312-317.
103. Belshe R.B., Edwards K.M., Vesikari T., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
104. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405-1412.
105. Bergen R., Black S., Shinefield H., et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004, 23:138-144.
106. Bracco Neto H., Farhat C.K., Tregnaghi M.W. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009, 28:365-371. D153-P504 LAIV Study Group.
107. King J.C., Lagos R., Bernstein D.I., et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998, 177:1394-1397.
108. Tam J.S., Capeding M.R., Lum L.C., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26:619-628.
109. Vesikari T., Fleming D.M., Aristegui J.F., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
110. Zangwill K.M., Droge J., Mendelman P., et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001, 20:740-746.
111. Ambrose C.S., Yi T., Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children 2-17 years. Influenza Other Respi Viruses 2011, 5:389-397.
112. Izurieta H.S., Haber P., Wise R.P., et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005, 294:2720-2725.
113. Hobson D., Curry R.L., Beare A.S., et al. The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972, 70:767-777.
114. Murphy B.R., Phelan M.A., Nelson D.L., et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981, 13:554-560.
115. Block S.L., Yogev R., Hayden F.G., et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26:4940-4946.
116. Treanor J.J., Kotloff K., Betts R.F., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 2000, 18:899-906.
117. Gruber W.C., Belshe R.B., King J.C., et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996, 173:1313-1319.
118. Lee M.S., Mahmood K., Adhikary L., et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004, 23:852-856.
119. Nolan T., Lee M.S., Cordova J.M., et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 2003, 21:1224-1231.
120. Swierkosz E.M., Newman F.K., Anderson E.L., et al. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994, 169:1121-1124.
121. Corti D., Suguitan A.L.J., Pinna D., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
122. Ekiert D.C., Bhabha G., Elsliger M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
123. Kashyap A.K., Steel J., Oner A.F., et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008, 105:5986-5991.
124. Okuno Y., Isegawa Y., Sasao F., et al. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552-2558.
125. Sui J., Hwang W.C., Perez S., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
126. Steel J., Lowen A.C., Wang T.T., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1. pii: e00018-10.
127. Clements M.L., Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986, 23:66-72.
128. Sasaki S., He X.S., Holmes T.H., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008, 3:e2975.
129. Sasaki S., Jaimes M.C., Holmes T.H., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228.
130. Clements M.L., Betts R.F., Tierney E.L., et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24:157-160.
131. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
132. Subbarao K., Murphy B.R., Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 2006, 24:5-9.
133. Forrest D.B., Pride M.W., Dunning A.J., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
134. He X.S., Holmes T.H., Zhang C., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80:11756-11766.
135. Basha S., Hazenfeld S., Brady R.C., et al. Comparison of antibody and T-cell responses elicited by licensed inactivated-and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011, 72:463-469.
136. Lanthier P.A., Huston G.E., Moquin A., et al. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 2011, 29:7849-7856.
137. Gaucher D., Therrien R., Kettaf N., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205:3119-3131.
138. Querec T.D., Akondy R.S., Lee E.K., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
139. Nakaya H.I., Wrammert J., Lee E.K., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
140. Zhu W., Higgs B.W., Morehouse C., et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 2010, 28:2865-2876.
141. Petrie J.G., Ohmit S.E., Johnson E., et al. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011, 203:1309-1315.
142. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
143. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
144. Clements M.L., Betts R.F., Murphy B.R. Advantage of live attenuated cold-adapted influenza virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984, 1:705-708.
145. Clements M.L., Betts R.F., Tierney E.L., et al. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986, 23:73-76.
146. Sears S.D., Clements M.L., Betts R.F., et al. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988, 158:1209-1219.
147. Clements M.L., Snyder M.H., Sears S.D., et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990, 161:869-877.
148. Edwards K.M., Dupont W.D., Westrich M.K., et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169:68-76.
149. Monto A.S., Ohmit S.E., Petrie J.G., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
150. Ohmit S.E., Victor J.C., Rotthoff J.R., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
151. Belshe R.B., Coelingh K., Ambrose C.S., et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28:2149-2156.
152. Belshe R.B., Ambrose C.S., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26(suppl 4):D10-D16.
153. Block S.L., Toback S.L., Yi T., et al. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther 2009, 31:2140-2147.
154. Bridges C.B., Thompson W.W., Meltzer M.I., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000, 284:1655-1663.
155. Nichol K.L., Mendelman P.M., Mallon K.P., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282:137-144.
156. Belshe R.B., Gruber W.C. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000, 19(suppl 5):S66-S71.
157. Gaglani M.J., Piedra P.A., Herschler G.B., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004, 158:65-73.
158. Bernstein D.I., Yan L., Treanor J. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003, 22:28-34. Cold-Adapted, Trivalent, Influenza Vaccine Study Group.
159. Johnson P.R.J., Feldman S., Thompson J.M., et al. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985, 17:325-335.
160. Ambrose C.S., Yi T., Walker R.E., et al. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008, 27:744-748.
161. de Jong J.C., Palache A.M., Beyer W.E.P., et al. Hemagglutination-inhibiting antibody to influenza virus. Laboratory Correlates of Immunity to Influenza: A Reassessment 2003, 63-73. Karger, Basel, Switzerland. F. Brown, L.R. Haaheim, G.C. Schild (Eds.).
162. Ohmit S.E., Petrie J.G., Cross R.T., et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204:1879-1885.
163. Center for Biologics Evaluation and Research Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines 2007, U.S. Food and Drug Administration, Rockville, MD.
164. Belshe R.B., Van Voris L.P., Bartram J., et al. Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis 1984, 150:834-840.
165. He X.S., Holmes T.H., Sasaki S., et al. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One 2008, 3:e2574.
166. Ambrose C.S., Luke C., Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008, 2:193-202.
167. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011, 5:67-75.
168. Neuzil K.M., Dupont W.D., Wright P.F., et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001, 20:733-740.
169. Fleming D.M., Crovari P., Wahn U., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolscents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
170. Ambrose C.S., Dubovsky F., Yi T. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis March 2012, E pub Mar 14. DOI 10.1007/s10096-012-1595-9.
171. Ashkenazi S., Vertruyen A., Aristegui J., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
172. Ambrose C.S., Wu X., Belshe R.B. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010, 29:806-811.
173. Jefferson T., Smith S., Demicheli V., et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005, 365:773-780.
174. Rhorer J., Ambrose C.S., Dickinson S., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
175. Belshe R.B., Toback S.L., Yi T., et al. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010, 4:141-145.
176. Block S.L., Heikkinen T., Toback S.L., et al. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011, 30:203-207.
177. Eick A.A., Wang Z., Hughes H., et al. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009, 27:3568-3575.
178. Wang Z., Tobler S., Roayaei J., et al. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illness among US military personnel. JAMA 2009, 301:945-953.
179. Redding G., Walker R.E., Hessel C., et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002, 21:44-48.
180. Tennis P., Toback S.L., Andrews E., et al. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 2011, 29:4947-4952.
181. Ferson M.J., Morton J.R., Robertson P.W. Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health 1991, 27:308-311.
182. Gruber W.C., Campbell P.W., Thompson J.M., et al. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis 1994, 169:241-247.
183. King J.C., Treanor J., Fast P.E., et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181:725-728.
184. King J.C., Fast P.E., Zangwill K.M., et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20:1124-1131.
185. Levin M.J., Song L.Y., Fenton T., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26:4210-4217.
186. Weinberg A., Song L.Y., Walker R., et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010, 55:189-196.
187. Halasa N., Englund J.A., Nachman S., et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011, 29:4110-4115.
188. Fiore A.E., Uyeki T.M., Broder K. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59(RR-8):1-62. Centers for Disease Control and Prevention.
189. De Villiers P.J.T., Steele A.D., Hiemstra L.A., et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28:228-234.
190. Gorse G.J., O'Connor T.Z., Newman F.K., et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004, 190:11-19.
191. Gorse G.J., O'Connor T.Z., Young S.L., et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003, 21:2133-2144.
192. Gorse G.J., Otto E.E., Powers D.C., et al. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis 1996, 173:285-290.
193. Jackson L.A., Holmes S.J., Mendelman P.M., et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999, 17:1905-1909.
194. Powers D.C., Fries L.F., Murphy B.R., et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991, 29:498-505.
195. Powers D.C., Sears S.D., Murphy B.R., et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989, 27:2666-2671.
196. Treanor J.J., Mattison H.R., Dumyati G., et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992, 117:625-633.
197. Treanor J.J., Betts R.F., Smith G.E., et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996, 173:1467-1470.
198. Forrest B.D., Steele A.D., Hiemstra L., et al. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011, 29:3633-3639.
199. John T.J., Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000, 16:601-606.
200. Glezen W.P. Herd protection against influenza. J Clin Virol 2006, 37:237-243.
201. Simonsen L., Reichert T.A., Viboud C., et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005, 165:265-272.
202. Simonsen L., Taylor R.J., Viboud C., et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7:658-666.
203. Carman W.F., Elder A.G., Wallace L.A., et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000, 355:93-97.
204. Hayward A.C., Harling R., Wetten S., et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006, 333:1241-1246.
205. Lemaitre M., Meret T., Rothan-Tondeur M., et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc 2009, 57:1580-1586.
206. Potter J., Stott D.J., Roberts M.A., et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997, 175:1-6.
207. Thomas R.E., Jefferson T.O., Demicheli V., et al. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis 2006, 6:273-279.
208. Monto A.S., Davenport F.M., Napier J.A., et al. Modification of an outbreak of influenza in Tecumseh, Michigan, by vaccination of schoolchildren. J Infect Dis 1970, 122:16-25.
209. Reichert T.A., Sugaya N., Fedson D.S., et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344:889-896.
210. Rudenko L.G., Slepushkin A.N., Monto A.S., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod. Russia. J Infect Dis 1993, 168:881-887.
211. Piedra P.A., Gaglani M.J., Kozinetz C.A., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005, 23:1540-1548.
212. Piedra P.A., Gaglani M.J., Kozinetz C.A., et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007, 120:e553-e564.
213. Glezen W.P., Gaglani M.J., Kozinetz C.A., et al. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010, 202:1626-1633.
214. King J.C., Cummings G.E., Stoddard J., et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005, 116:e868-e873.
215. King J.C., Stoddard J.J., Gaglani M.J., et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006, 355:2523-2532.
216. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006, 193:49-53.
217. Slepushkin A.N. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull World Health Organ 1959, 20:297-301.
218. Nguyen H.H., Moldoveanu Z., Novak M.J., et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 1999, 254:50-60.
219. Powell T.J., Strutt T., Reome J., et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 2007, 178:1030-1038.
220. Schulman J.L., Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 1965, 89:170-174.
221. Yetter R.A., Barber W.H., Small P.A. Heterotypic immunity to influenza in ferrets. Infect Immun 1980, 29:650-653.
222. Steinhoff M.C., Fries L.F., Karron R.A., et al. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 1993, 31:836-838.
223. Smith D.B., Inglis S.C. The mutation rate and variability of eukaryotic viruses: an analytical review. J Gen Virol 1987, 68:2729-2740.
224. Buonagurio D.A., Bechert T.M., Yang C., et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 2006, 24:2151-2160.
225. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
226. Cha T., Kao K., Zhao J., et al. Genetic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000, 38:839-845.
227. Vesikari T., Karvonen A., Korhonen T., et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006, 25:590-595.
228. Buonagurio D.A., O'Neill R.E., Shutyak L., et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 2006, 347:296-306.
229. Mallory R.M., Malkin E., Ambrose C.S., et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010, 5:e13755.
230. Rudenko L., van den Bosch H., Kiseleva I., et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29(suppl. 1):A40-A44.
231. Griffin M.R., Monto A.S., Belongia E.A. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011, 6:e23085. for the U.S. Flu-VE Network.
232. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec 2010, 85:81-92.
233. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. Wkly Epidemiol Rec 2011, 86:81-90.
234. Karron R.A., Callahan K., Luke C., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009, 199:711-716.
235. Karron R.A., Talaat K., Luke C., et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009, 27:4953-4960.
236. Talaat K.R., Karron R.A., Callahan K.A., et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
237. Talaat K.R., Karron R.A., Luke C.J., et al. An open-label phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011, 29:3144-3148.
238. Talaat K.R., Karron R.A., Liang P.H. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respi Viruses 2012, DOI:10.1111/j.1750-2659.2012.00350.x.
239. Rudenko L., Desheva J., Korovkin S., et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respi Viruses 2008, 2:203-209.
240. Romanova J., Krenn B.M., Wolschek M., et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009, 4:e5984.
241. Steel J., Lowen A.C., Pena L., et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009, 83:1742-1753.
242. Girard M.P., Katz J., Pervikov Y., et al. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials. World Health Organization; Geneva, Switzerland; 17-18 February 2010. Vaccine 2010, 28:6811-6820.
243. Watanabe T., Watanabe S., Kim J.H., et al. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 2008, 82:2486-2492.
244. DiNapoli J.M., Yang L., Suguitan A., et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 2007, 81:11560-11568.
245. Belshe R.B., Van Voris L.P. Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis 1984, 149:735-740.
246. Couch R.B., Quarles J.M., Cate T.R., et al. Clinical trials with live cold-reassortant influenza virus vaccines. Options for the Control of Influenza 1986, 223-241. Alan R. Liss, New York. A.P. Kendal, P.A. Patriarca (Eds.).
247. Davenport F.M., Hennessy A.V., Minuse E., et al. Pilot studies on mono and bivalent live attenuated influenza virus vaccines. Proceedings of the Symposium on Live Influenza Vaccine 1971, 105-113. Yugoslav Academy of Sciences and Arts, Zagreb. B. Guesiac (Ed.).
248. Moritz A.J., Kunz C., Hofmann H., et al. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus, II: evaluation in adult volunteers. J Infect Dis 1980, 142:857-860.
249. Reeve P., Gerendas B., Moritz A., et al. Studies in man with cold-recombinant influenza virus (H1N1) live vaccines. J Med Virol 1980, 6:75-83.
250. van Voorthuizen F., Jens D., Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains. Antiviral Res 1981, 1:107-122.
251. Wright P.F., Johnson P.R., Karzon D.T. Clinical experience with live, attenuated vaccines in children. Options for the Control of Influenza 1986, 243-253. Alan R. Liss, New York. A.P. Kendal, P.A. Patriarca (Eds.).
252. Mallory R.M., Yi T., Ambrose C.S. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine 2011, 29:4322-4327.
253. Hoft D.F., Babusis E., Worku S., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011, 204:845-853.
254. Nolan T., Bernstein D.I., Block S.L., et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008, 121:508-516.